Literature DB >> 19948722

Inducible priming phosphorylation promotes ligand-independent degradation of the IFNAR1 chain of type I interferon receptor.

Sabyasachi Bhattacharya1, Wei-Chun HuangFu, Jianghuai Liu, Sudhakar Veeranki, Darren P Baker, Constantinos Koumenis, J Alan Diehl, Serge Y Fuchs.   

Abstract

Phosphorylation-dependent ubiquitination and ensuing down-regulation and lysosomal degradation of the interferon alpha/beta receptor chain 1 (IFNAR1) of the receptor for Type I interferons play important roles in limiting the cellular responses to these cytokines. These events could be stimulated either by the ligands (in a Janus kinase-dependent manner) or by unfolded protein response (UPR) inducers including viral infection (in a manner dependent on the activity of pancreatic endoplasmic reticulum kinase). Both ligand-dependent and -independent pathways converge on phosphorylation of Ser(535) within the IFNAR1 degron leading to recruitment of beta-Trcp E3 ubiquitin ligase and concomitant ubiquitination and degradation. Casein kinase 1 alpha (CK1 alpha) was shown to directly phosphorylate Ser(535) within the ligand-independent pathway. Yet given the constitutive activity of CK1 alpha, it remained unclear how this pathway is stimulated by UPR. Here we report that induction of UPR promotes the phosphorylation of a proximal residue, Ser(532), in a pancreatic endoplasmic reticulum kinase-dependent manner. This serine serves as a priming site that promotes subsequent phosphorylation of IFNAR1 within its degron by CK1 alpha. These events play an important role in regulating ubiquitination and degradation of IFNAR1 as well as the extent of Type I interferon signaling.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19948722      PMCID: PMC2807289          DOI: 10.1074/jbc.M109.071498

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  47 in total

1.  Characterization of antihuman IFNAR-1 monoclonal antibodies: epitope localization and functional analysis.

Authors:  L A Goldman; M Zafari; E C Cutrone; A Dang; M Brickelmeier; L Runkel; C D Benjamin; L E Ling; J A Langer
Journal:  J Interferon Cytokine Res       Date:  1999-01       Impact factor: 2.607

2.  Expression and signaling specificity of the IFNAR chain of the type I interferon receptor complex.

Authors:  S N Constantinescu; E Croze; A Murti; C Wang; L Basu; D Hollander; D Russell-Harde; M Betts; V Garcia-Martinez; J E Mullersman; L M Pfeffer
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-07       Impact factor: 11.205

3.  Phosphorylation and specific ubiquitin acceptor sites are required for ubiquitination and degradation of the IFNAR1 subunit of type I interferon receptor.

Authors:  K G Suresh Kumar; John J Krolewski; Serge Y Fuchs
Journal:  J Biol Chem       Date:  2004-08-26       Impact factor: 5.157

Review 4.  Immunotherapy for HCV infection: next steps.

Authors:  Krystle Lang; David B Weiner
Journal:  Expert Rev Vaccines       Date:  2008-09       Impact factor: 5.217

5.  Determinants on simian virus 40 large T antigen are important for recognition and phosphorylation by casein kinase I.

Authors:  J L Umphress; P T Tuazon; C J Chen; J A Traugh
Journal:  Eur J Biochem       Date:  1992-01-15

Review 6.  Pegylated and non-pegylated interferon-alfa and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and meta-analysis.

Authors:  Debbie Hartwell; Jonathan Shepherd
Journal:  Int J Technol Assess Health Care       Date:  2009-01       Impact factor: 2.188

7.  Cigarette smoking products suppress anti-viral effects of Type I interferon via phosphorylation-dependent downregulation of its receptor.

Authors:  Wei-Chun HuangFu; Jianghuai Liu; Ronald N Harty; Serge Y Fuchs
Journal:  FEBS Lett       Date:  2008-08-21       Impact factor: 4.124

8.  Virus-induced unfolded protein response attenuates antiviral defenses via phosphorylation-dependent degradation of the type I interferon receptor.

Authors:  Jianghuai Liu; Wei-Chun HuangFu; K G Suresh Kumar; Juan Qian; James P Casey; Robert B Hamanaka; Christina Grigoriadou; Rafael Aldabe; J Alan Diehl; Serge Y Fuchs
Journal:  Cell Host Microbe       Date:  2009-01-22       Impact factor: 21.023

9.  Functional role of type I and type II interferons in antiviral defense.

Authors:  U Müller; U Steinhoff; L F Reis; S Hemmi; J Pavlovic; R M Zinkernagel; M Aguet
Journal:  Science       Date:  1994-06-24       Impact factor: 47.728

10.  Role of interferon alpha/beta receptor chain 1 in the structure and transmembrane signaling of the interferon alpha/beta receptor complex.

Authors:  S N Constantinescu; E Croze; C Wang; A Murti; L Basu; J E Mullersman; L M Pfeffer
Journal:  Proc Natl Acad Sci U S A       Date:  1994-09-27       Impact factor: 11.205

View more
  35 in total

1.  Ubiquitination-dependent regulation of signaling receptors in cancer.

Authors:  Wei-Chun Huangfu; Serge Y Fuchs
Journal:  Genes Cancer       Date:  2010-07

Review 2.  Eliminative signaling by Janus kinases: role in the downregulation of associated receptors.

Authors:  Christopher J Carbone; Serge Y Fuchs
Journal:  J Cell Biochem       Date:  2014-01       Impact factor: 4.429

3.  Suppression of Type I Interferon Signaling Overcomes Oncogene-Induced Senescence and Mediates Melanoma Development and Progression.

Authors:  Yuliya V Katlinskaya; Kanstantsin V Katlinski; Qiujing Yu; Angelica Ortiz; Daniel P Beiting; Angela Brice; Diwakar Davar; Cindy Sanders; John M Kirkwood; Hallgeir Rui; Xiaowei Xu; Constantinos Koumenis; J Alan Diehl; Serge Y Fuchs
Journal:  Cell Rep       Date:  2016-03-24       Impact factor: 9.423

4.  Type 1 interferons contribute to the clearance of senescent cell.

Authors:  Yuliya V Katlinskaya; Christopher J Carbone; Qiujing Yu; Serge Y Fuchs
Journal:  Cancer Biol Ther       Date:  2015-06-05       Impact factor: 4.742

5.  Expression of the IFNAR1 chain of type 1 interferon receptor in benign cells protects against progression of acute leukemia.

Authors:  Bin Zhao; Sabyasachi Bhattacharya; Qiujing Yu; Serge Y Fuchs
Journal:  Leuk Lymphoma       Date:  2017-05-15

Review 6.  Ubiquitination-mediated regulation of interferon responses.

Authors:  Serge Y Fuchs
Journal:  Growth Factors       Date:  2012-03-07       Impact factor: 2.511

7.  An Interferon-Driven Oxysterol-Based Defense against Tumor-Derived Extracellular Vesicles.

Authors:  Angelica Ortiz; Jun Gui; Farima Zahedi; Pengfei Yu; Christina Cho; Sabyasachi Bhattacharya; Christopher J Carbone; Qiujing Yu; Kanstantsin V Katlinski; Yuliya V Katlinskaya; Simran Handa; Victor Haas; Susan W Volk; Angela K Brice; Kim Wals; Nicholas J Matheson; Robin Antrobus; Sonja Ludwig; Theresa L Whiteside; Cindy Sander; Ahmad A Tarhini; John M Kirkwood; Paul J Lehner; Wei Guo; Hallgeir Rui; Andy J Minn; Constantinos Koumenis; J Alan Diehl; Serge Y Fuchs
Journal:  Cancer Cell       Date:  2019-01-14       Impact factor: 31.743

8.  Jun activation domain-binding protein 1 (JAB1) is required for the optimal response to interferons.

Authors:  Ryuta Muromoto; Maiko Nakajima; Koki Hirashima; Toru Hirao; Shigeyuki Kon; Kazuya Shimoda; Kenji Oritani; Tadashi Matsuda
Journal:  J Biol Chem       Date:  2013-09-16       Impact factor: 5.157

9.  Anti-tumorigenic effects of Type 1 interferon are subdued by integrated stress responses.

Authors:  S Bhattacharya; W-C HuangFu; G Dong; J Qian; D P Baker; J Karar; C Koumenis; J A Diehl; S Y Fuchs
Journal:  Oncogene       Date:  2012-10-08       Impact factor: 9.867

10.  Therapeutic Elimination of the Type 1 Interferon Receptor for Treating Psoriatic Skin Inflammation.

Authors:  Jun Gui; Michael Gober; Xiaoping Yang; Kanstantsin V Katlinski; Christine M Marshall; Meena Sharma; Victoria P Werth; Darren P Baker; Hallgeir Rui; John T Seykora; Serge Y Fuchs
Journal:  J Invest Dermatol       Date:  2016-06-29       Impact factor: 8.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.